catalyst calendar
/
← Catalyst calendar

SPTX biotech catalysts & pipeline

SEAPORT THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

allopregnanolone (SPT-300) — Topline data

in 1H 2027

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Source filing

agomelatine (SPT-320) — Topline data

early 2028

Seaport has initiated a Phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance, with topline results expected in early 2028.
Source filing

Explore the free biotech catalyst calendar